Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
QBW251 - CFTR potentiator
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04072887 (CQBW251B2201)
Chronic obstructive pulmonary disease (COPD)
Phase 2
956
Trough FEV1 (Forced Expiratory Volume in 1 second) change from baseline after
12 weeks of treatment
QBW251 450 mg
Target Patients
QBW251 300 mg
QBW251 150 mg
QBW251 75 mg
QBW251 25 mg
Placebo
COPD patients on background triple inhaled therapy (LABA / LAMA / ICS)
Read-out Milesstone(s)
Publication
H1-2022
Primary publications planned for 2022
129 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation